Tevogen Complements Capital Access with Two-Year Extension to Loan Agreement

The amended facility permits up to $28.6 million in borrowings, with repayment allowed in cash or shares under applicable terms.

Rhea-AI Summary

Tevogen (Nasdaq: TVGN) extended the borrowing period under its existing loan agreement with The Patel Family to May 2029.

The amendment moves the borrowing deadline from May 2027 and permits borrowings of up to $28.6 million, subject to the agreement’s terms and conditions. Repayment may be made in cash or shares, subject to applicable terms. The facility complements an existing at-the-market equity program originally established for up to $50 million in aggregate sales. Tevogen is not obligated to sell shares, and any sales depend on market conditions and applicable requirements.

2 points · 1 major

MixediHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

1 major · 3 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Major point. Forward-looking: it has not happened yet and may not happen.Amended facility permits up to $28.6 million in borrowings. 31% of market cap
• Moderate pointBorrowing access extended two years, from May 2027 to May 2029, under the existing loan agreement.

Negative

• Major point. Forward-looking: it has not happened yet and may not happen.Loan repayment may use shares, subject to applicable terms, potentially diluting existing holders.
• Moderate point. Forward-looking: it has not happened yet and may not happen.Existing equity program permits up to $50 million in aggregate sales; optional share sales could dilute holders. 53% of market cap
• Minor pointBorrowing availability remains subject to the agreement’s terms and conditions.

News Explained

At June 30, 2026, Tevogen reported $1,082,155 in cash, equal to 32.8 days of its second-quarter operating cash use; this is a historical comparison, not a projection of future cash runway.

Sources and calculations

• Tevogen 2026 second-quarter fundamentals (2026Q2)
• Tevogen loan agreement extension release (2026-11-09)

• Available liquidity against the last reported quarterly operating outflow, in days at that rate $1,082,155 / ($3,005,403 / 91) = 32.8 days

Key Figures

Borrowing-period extension: May 2027 to May 2029 Maximum borrowing capacity: Up to $28.6 million ATM program sales capacity: Up to $50 million

Borrowing-period extension

May 2027 to May 2029

End of the borrowing period under the existing loan agreement

Maximum borrowing capacity

Up to $28.6 million

Amended loan facility; subject to the agreement’s terms and conditions

ATM program sales capacity

Up to $50 million

Aggregate sales capacity under the existing ATM equity program

Key Terms

atm equity program, form 8-k

2 terms

atm equity program financial

"The facility complements Tevogen’s existing ATM equity program"

An at‑the‑market (ATM) equity program is a way a company sells its own shares directly into the open market, bit by bit, at prevailing market prices instead of issuing a large block all at once. Think of it like a faucet the company can turn on when it needs cash; it provides flexible funding but can dilute existing shareholders and put downward pressure on the stock if used heavily, so investors watch size and timing closely.

form 8-k regulatory

"Additional information on the amendment appears in the Company’s Form 8-K filed with the SEC"

A Form 8-K is a report that companies file with the government to share important news quickly, such as changes in leadership, major business deals, or financial updates. It matters because it helps investors stay informed about significant events that could affect the company's value or stock price.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• Up to $28.6 million in borrowing capacity through May 2029
  

WARREN, N.J., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Tevogen Inc. (“Tevogen” or the “Company”) (Nasdaq: TVGN), a healthcare company focused on combining biopharma, artificial intelligence, and healthcare services to improve the affordability and accessibility of life-saving medicines, has extended the end of the borrowing period under its existing loan agreement with The Patel Family, LLP from May 2027 to May 2029. The facility permits borrowings of up to $28.6 million under the amended agreement, subject to the agreement’s terms and conditions.

The facility complements Tevogen’s existing ATM equity program, originally established to provide for up to $50 million in aggregate sales. Tevogen is not obligated to sell any shares under the program, and any sales are subject to market conditions and applicable requirements.

“We intend to remain selective about financing decisions and disciplined in our use of capital,” said Ryan Saadi, MD, MPH, Founder and CEO of Tevogen.

The loan agreement permits repayment in cash or shares, subject to applicable terms. Additional information on the amendment appears in the Company’s Form 8-K filed with the SEC regarding the amendment.

About Tevogen

Tevogen is a healthcare enterprise focused on improving the affordability and accessibility of life-saving medicines. The Company brings together three complementary efforts: Tevogen Bio, its biotechnology initiative; Tevogen.AI, its artificial intelligence and technology initiative; and Tevogen Healthcare Services, its emerging healthcare services initiative.

Together, these efforts are designed to create a more integrated healthcare model in which science, technology, and operational efficiency work together to reduce the cost of medication and expand patient access.

Forward Looking Statements

This press release contains certain forward-looking statements, including without limitation statements relating to: Tevogen’s expectations regarding the availability, amount, timing, and terms of future financing, including borrowings under its amended credit agreement and sales under its at-the-market equity program; the potential repayment of borrowings in cash or shares; the Company’s intentions regarding financing terms and disciplined use of capital; and the anticipated benefits of combining its biotechnology, artificial intelligence, and healthcare services initiatives, including reducing medication costs and improving patient access. Forward-looking statements can sometimes be identified by words such as “may,” “could,” “would,” “expect,” “anticipate,” “intend,” “plan,” “possible,” “potential,” “goal,” “opportunity,” “project,” “believe,” “future,” and similar words and expressions or their opposites. These statements are based on management’s expectations, assumptions, estimates, projections, and beliefs as of the date of this press release and are subject to known and unknown risks, delays, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied by these forward-looking statements.

Factors that could cause actual results, performance, or achievements to differ include, but are not limited to: the risk that financing under the amended credit agreement or at-the-market equity program may not be available in the amounts, at the times, or on the terms anticipated; the ability of the Company and its financing counterparties to satisfy applicable conditions and perform their obligations; market conditions, the trading price and volume of the Company’s common stock, and applicable contractual, securities law, registration, and stock exchange requirements that may limit borrowings, share sales, or repayment in shares; changes in the Company’s operating costs, capital requirements, and financing needs; the need to raise additional capital to fully realize the Company’s business plans; the risk that the Company may not achieve its intended capital allocation objectives or realize the anticipated benefits of its business initiatives; changes in the markets in which Tevogen competes, including competition, technological developments, and regulatory changes; changes in domestic and global economic conditions; difficulties in executing business strategies, managing growth, and hiring and retaining key employees; risks related to the development, licensing, acquisition, regulatory approval, and commercialization of therapeutics and technologies; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks associated with intellectual property protection; the Company’s ability to develop and maintain effective internal controls; and those factors discussed or incorporated by reference in Tevogen’s most recent Annual Report on Form 10-K and subsequent filings with the SEC.

You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law.

Contacts

Tevogen Communications
T: 1 877 TEVOGEN, Ext 701
Communications@Tevogen.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How long did Tevogen extend its loan borrowing period, and how much can it borrow?

Tevogen extended the borrowing period from May 2027 to May 2029. The amended agreement with The Patel Family permits borrowings of up to $28.6 million, subject to its terms and conditions.